Reid JM - Search Results

1

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.

Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C. Pitot HC, et al. Among authors: reid jm. Cancer Chemother Pharmacol. 2006 Aug;58(2):165-72. doi: 10.1007/s00280-005-0138-9. Epub 2005 Nov 19. Cancer Chemother Pharmacol. 2006. PMID: 16328416 Clinical Trial.

2

Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720].

Reid JM, Mathiesen DA, Benson LM, Kuffel MJ, Ames MM. Reid JM, et al. Cancer Res. 1992 May 15;52(10):2830-4. Cancer Res. 1992. PMID: 1581896

3

Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Kuffel MJ, Reid JM, Ames MM. Kuffel MJ, et al. Among authors: reid jm. Cancer Chemother Pharmacol. 1992;30(1):51-7. doi: 10.1007/BF00686485. Cancer Chemother Pharmacol. 1992. PMID: 1586980

4

Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.

Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Reid JM, et al. Cancer Res. 1990 Oct 15;50(20):6525-8. Cancer Res. 1990. PMID: 2208112 Clinical Trial.

5

Preclinical pharmacology of cholera toxin.

Reid JM, Benson JW, Viallet J, Ames MM. Reid JM, et al. Cancer Chemother Pharmacol. 1995;36(2):115-20. doi: 10.1007/BF00689194. Cancer Chemother Pharmacol. 1995. PMID: 7767946

6

Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.

Dhodapkar MV, Richardson RL, Reid JM, Ames MM. Dhodapkar MV, et al. Among authors: reid jm. Invest New Drugs. 1994;12(3):207-16. doi: 10.1007/BF00873961. Invest New Drugs. 1994. PMID: 7896539 Clinical Trial.

7

Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065.

Walker DL, Reid JM, Ames MM. Walker DL, et al. Among authors: reid jm. Cancer Chemother Pharmacol. 1994;34(4):317-22. doi: 10.1007/BF00686039. Cancer Chemother Pharmacol. 1994. PMID: 8033298

8

Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity.

Reid JM, Walker DL, Ames MM. Reid JM, et al. Cancer Chemother Pharmacol. 1996;38(4):329-34. doi: 10.1007/s002800050491. Cancer Chemother Pharmacol. 1996. PMID: 8674155

9

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH. Adjei AA, et al. Among authors: reid jm. Clin Cancer Res. 1998 Mar;4(3):683-91. Clin Cancer Res. 1998. PMID: 9533538

10

Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.

Reid JM, Kovach JS, O'Connell MJ, Bagniewski PG, Moertel CG. Reid JM, et al. Cancer Chemother Pharmacol. 1998;41(6):477-84. doi: 10.1007/s002800050770. Cancer Chemother Pharmacol. 1998. PMID: 9554592 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

517 results

Search Page

Filters